Novartis: Novartis receives US FDA accelerated approval for Vanrafia, the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy

Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of